FDA grants Breakthrough Therapy Designation for Roche ’s Hemlibra in haemophilia A without inhibitors

Roche today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra ® (emicizumab-kxwh) for people with haemophilia A without factor VIII inhibitors.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news